Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.49 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1944073 | 0.93 | HRH3 (0.51) | SIGMAR1HRH3EGLN1 | |
| SCHEMBL1946373 | 0.81 | ITGB3 (0.57) | HRH3EGLN1ITGB3ITGA2B | |
| SCHEMBL1944492 | 0.79 | EGLN1 (0.45) | SIGMAR1KMT2AHRH3EGLN1ITGB3 | |
| SCHEMBL1947264 | 0.78 | HRH3 (0.54) | HRH3EGLN1ITGB3ITGA2B | |
| SCHEMBL745418 | 0.78 | HRH3 (0.49) | TSHRHRH3EGLN1 | |
| SCHEMBL1944541 | 0.77 | SLC18A3 (0.49) | MEN1KMT2AHRH3EGLN1ITGB3 | |
| SCHEMBL1944540 | 0.77 | SLC18A3 (0.49) | MEN1KMT2AHRH3EGLN1ITGB3 | |
| SCHEMBL1944543 | 0.77 | SLC18A3 (0.49) | MEN1KMT2AHRH3EGLN1ITGB3 | |
| SCHEMBL1961559 | 0.77 | SIGMAR1 (0.46) | SIGMAR1CYP2D6TSHRHRH3 | |
| SCHEMBL1945920 | 0.77 | ALDH1A1 (0.47) | MEN1KMT2AHRH3EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2507239-B1 | AZACYCLIC SPIRO DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2019-03-13 | — | — | EP | claimed |
| US-8389539-B2 | Azacyclic derivatives | HOFFMAN-LA ROCHE INC. (US) | 2013-03-05 | — | — | US | claimed |
| EP-2507239-A1 | AZACYCLIC SPIRO DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2012-10-10 | — | — | EP | claimed |
| WO-2011067166-A1 | AZACYCLIC SPIRO DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-09 | — | — | WO | claimed |
| US-20110130417-A1 | NEW AZACYCLIC DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2011-06-02 | — | — | US | claimed |
| EP-2507239-B1 | AZACYCLIC SPIRO DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2019-03-13 | — | — | EP | disclosed |
| EP-2507239-B1 | AZACYCLIC SPIRO DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2019-03-13 | — | — | EP | disclosed |
| US-8389539-B2 | Azacyclic derivatives | HOFFMAN-LA ROCHE INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389539-B2 | Azacyclic derivatives | HOFFMAN-LA ROCHE INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389539-B2 | Azacyclic derivatives | HOFFMAN-LA ROCHE INC. (US) | 2013-03-05 | — | — | US | disclosed |
| EP-2507239-A1 | AZACYCLIC SPIRO DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2012-10-10 | — | — | EP | disclosed |
| WO-2011067166-A1 | AZACYCLIC SPIRO DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-09 | — | — | WO | disclosed |
| WO-2011067166-A1 | AZACYCLIC SPIRO DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-09 | — | — | WO | disclosed |
| US-20110130417-A1 | NEW AZACYCLIC DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2011-06-02 | — | — | US | disclosed |
| US-20110130417-A1 | NEW AZACYCLIC DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2011-06-02 | — | — | US | disclosed |
| US-20110130417-A1 | NEW AZACYCLIC DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130417-A1 | NEW AZACYCLIC DERIVATIVES | AZI2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, UGT1A1 | SIGMAR1 337/4885MEN1 379/4885TP53 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.